Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor-Reference-Cited by-同舟云学术

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Published:2022-10 Issue:10 Volume:28 Page:2171-2182
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Hallin Jill^ORCID,Bowcut Vickie,Calinisan Andrew,Briere David M.,Hargis Lauren,Engstrom Lars D.^ORCID,Laguer Jade,Medwid James,Vanderpool Darin,Lifset Ella,Trinh David,Hoffman Natalie,Wang Xiaolun,David Lawson J.^ORCID,Gunn Robin J.,Smith Christopher R.^ORCID,Thomas Nicole C.,Martinson Matthew,Bergstrom Alex,Sullivan Francis,Bouhana Karyn,Winski Shannon,He Leo,Fernandez-Banet Julio,Pavlicek Adam,Haling Jacob R.,Rahbaek Lisa,Marx Matthew A.^ORCID,Olson Peter,Christensen James G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02007-7.pdf

Reference45 articles.

1. Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321–337 (2018).

2. Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).

3. Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).

4. Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020).

5. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma;Drug Resistance Updates;2024-11

2. Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma;Surgical Clinics of North America;2024-10

3. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel inKRAS-mutated colorectal cancer;2024-09-06

4. Advanced technologies for screening and identifying covalent inhibitors;TrAC Trends in Analytical Chemistry;2024-09

5. Ferroptosis in health and disease;Redox Biology;2024-09